Total | Asp299Asp | Asp299Gly | P | |
---|---|---|---|---|
n (%) | 138 | 125 (90.6) | 13 (9.4) | |
Oro-Hypopharyngeal SCC; n (%) | 37 | 34 (91.9) | 3 (8.1) | 0.76 |
Laryngeal SCC; n (%) | 101 | 90 (89.1) | 11 (10.9) | |
Mean age ± SD [years] | 61 ± 10 | 60 ± 10 | 63 ± 13 | 0.66 |
Median follow up [months] (range)# | 50 (0-129) | 52 (0-129) | 42 (8-98) | 0.37 |
Sex (male/female); n | 119/19 | 106/19 | 13/0 | 0.21 |
Smoking; n (%) | 124 (89.8) | 112 (89.6) | 12 (92.3) | 1.00 |
Mean pack years ± SD | 45 ± 25 | 45 ± 24.6 | 50 ± 29.6 | 0.62 |
Primary therapy | 0.02 | |||
Surgery alone; n (%) | 61 | 57 (45.6) | 4 (30.8) | |
Surgery + RCT§; n (%) | 54 | 51 (40.8) | 3 (23.1) | |
Primary RCT§; n (%) | 23 | 17 (13.6) | 6 (46.1) | |
AJCC stage | 0.53 | |||
I; n (%) | 25 | 22 (17.6) | 3 (23.1) | |
II; n (%) | 33 | 30 (24.0) | 3 (23.1) | |
III; n (%) | 25 | 22 (17.6) | 3 (23.1) | |
IVA; n (%) | 50 | 47 (37.6) | 3 (23.1) | |
IVB; n (%) | 3 | 2 (1.6) | 1 (7.6) | |
IVC; n (%) | 2 | 2 (1.6) | 0 (0.0) | |
Grade | 0.32 | |||
1; n (%) | 9 | 7 (5.6) | 2 (15.4) | |
2; n (%) | 96 | 87 (69.6) | 9 (69.2) | |
3-4; n (%) | 25 | 23 (18.4) | 2 (15.4) |